课题基金 / 基金详情

EFFECTS OF ATORVASTATIN IN TYPE III HYPERLIPIDEMIA--OPEN EXTENSION STUDY

EFFECTS OF ATORVASTATIN IN TYPE III HYPERLIPIDEMIA--OPEN EXTENSION STUDY
阿托伐他汀对Ⅲ型高脂血症的作用--开放扩展研究
批准号：
6116952
负责人：
D ROGER ILLINGWORTH
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116952
关键词：
antihypercholesterolemic agent blood lipoprotein metabolism clinical research clinical trials drug administration rate /duration drug screening /evaluation familial hyperlipoproteinemia type III human subject human therapy evaluation lovastatin metabolism disorder chemotherapy steroid metabolism

项目摘要

项目成果

D ROGER ILLINGWORTH的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study will compare the hypolipidemic effects and influence on lipoprotein and cholesterol metabolism gemfibrozil, simvastatin and atorvastatin in patients with type III hyperlipidemia. After a 4 week dietary baseline, patients will be treated in a random sequence with gemfibrozil (1,200 mg/day), simvastatin (40 mg/day) or atorvastatin (10 mg/day or 80 mg/day) each for 8 weeks; efficacy, metabolic effects and safety will be evaluated on each regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of simvastatin on postprandial hyperlipidemia
REGULAR AND SUSTAINED RELEASE SIMVISTATIN IN HYPERCHOLESTEROLEMIA
SIMVASTATIN ON STEROID HORMONE PRODUCTION IN MEN WITH HYPERCHOLESTEROLEMIA
THE EFFECTS OF HIGH DOSE SIMVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA